<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00478036</url>
  </required_header>
  <id_info>
    <org_study_id>06-1251</org_study_id>
    <nct_id>NCT00478036</nct_id>
  </id_info>
  <brief_title>Comparing Acular LS and Pred Forte in Reducing Post-selective Laser Trabeculoplasty Anterior Chamber Flare and Cells</brief_title>
  <official_title>A Randomized Prospective Double Masked Controlled Trial Comparing Ketorolac Tromethamine 0.4% and Prednisolone Acetate 1% in Reducing Post-selective Laser Trabeculoplasty Anterior Chamber Flare and Cells.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Investigators will compare, in a randomized, prospective, masked and controlled fashion
      the effect of a non-steroidal anti-inflammatory agent (Acular LS), a corticosteroid (Pred
      Forte) and a placebo (Refresh Tears) on patient discomfort, degree of intraocular pressure
      (IOP) lowering and degree of ocular inflammation following selective laser trabeculoplasty
      treatment for open angle glaucoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, many ophthalmologists use anti-inflammatory agents like corticosteroids and
      nonsteroidal anti-inflammatory agents (NSAIDs) as a preventative measure to control the
      post-selective laser trabeculoplasty (SLT) anterior chamber inflammation. Both classes of
      compounds reduce inflammation through the inhibition of the cyclooxygenase pathway, whereas
      the corticosteroid class also inhibits the lipoxygenase pathway of the arachidonic acid
      cascade. Although effective, topical corticosteroids are associated with increase in
      intraocular pressure (IOP), posterior subcapsular cataract formation, and reduced response to
      infection. These adverse side effects have not been reported to occur with topical NSAIDs,
      which are effective in controlling the pain after SLT along with the prevention and
      suppression of the ocular inflammation. There are ophthalmologists who forgo using the
      anti-inflammatory agents post SLT and prescribe Refresh Tears to their patients to comfort
      the treated eye.

      The significance of the study lies in assessing the efficacy of Acular LS, compared to Pred
      Forte and to Refresh Tears in reducing discomfort, inflammation and maximizing IOP lowering
      following SLT procedure for open angle glaucoma with the hope of resolving the dispute over
      the effective post-operative care in SLT patients.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    insufficient enrollment
  </why_stopped>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Interocular Pressure</measure>
    <time_frame>8 weeks</time_frame>
    <description>IOP, measured by Goldmann applanation tonometry</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>Acular LS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acular LS - 1 drop in treated eye, 4 times a day, for 4 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pred Forte</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pred Forte - 1 drop in treated eye, 4 times a day, for 4 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Refresh Tears</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Refresh Tears - 1 drop in treated eye, 4 times a day, for 4 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acular LS</intervention_name>
    <description>Details covered in arm description</description>
    <arm_group_label>Acular LS</arm_group_label>
    <other_name>KETOROLAC TROMETHAMINE 0.5% SOLUTION - OPHTHALMIC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pred Forte</intervention_name>
    <description>Details covered in arm description</description>
    <arm_group_label>Pred Forte</arm_group_label>
    <other_name>Prednisolone acetate ophthalmic suspension 1%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Refresh Tears</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Refresh Tears</arm_group_label>
    <other_name>CARBOXYMETHYLCELLULOSE SODIUM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with open angle glaucoma patients at the Rocky Mountain Lions Eye Institute
             Glaucoma Clinic.

          -  Able to provide written informed consent to participate.

          -  Must be the age of 18 years of age or older.

          -  Patients in which further intraocular pressure lowering by selective laser
             trabeculoplasty is necessary in the opinion of the treating physician.

        Exclusion Criteria:

          -  Patients with eye surgery in the prior six months.

          -  Patients with prior or current use of topical or systemic corticosteroids or NSAIDs.

          -  Patients with pre-existing anterior chamber inflammation.

          -  Patients with known sensitivity to any of the study medications.

          -  Due to the age range and the disease entity, special patient populations such as
             children or pregnant women will not be enrolled in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malik Y. Kahook, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rocky Mountain Lions Eye Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Eye Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2007</study_first_submitted>
  <study_first_submitted_qc>May 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2007</study_first_posted>
  <results_first_submitted>March 17, 2016</results_first_submitted>
  <results_first_submitted_qc>August 15, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 7, 2016</results_first_posted>
  <last_update_submitted>August 15, 2016</last_update_submitted>
  <last_update_submitted_qc>August 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glaucoma</keyword>
  <keyword>selective laser trabeculoplasty</keyword>
  <keyword>anterior chamber flare</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Carboxymethylcellulose Sodium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Prospective study participants will be identified by a routine clinic visit at Rocky Mountain Lions Eye Institute, University of Colorado, and need to undergo selective laser trabeculoplasty treatment for their glaucoma. A study investigator will make the initial patient contact for recruitment.</recruitment_details>
      <pre_assignment_details>The patients enrolled in this study will follow standard of care practice in regards to selective laser trabeculoplasty with the exception that the patients will be randomized 1:1:1 (Acular LS: Pred Forte: Refresh Tears) to the inflammation treatment given after the procedure.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Acular LS</title>
          <description>Acular LS - 1 drop in treated eye, 4 times a day, for 4 days
Acular LS: Details covered in arm description</description>
        </group>
        <group group_id="P2">
          <title>Pred Forte</title>
          <description>Pred Forte - 1 drop in treated eye, 4 times a day, for 4 days
Pred Forte: Details covered in arm description</description>
        </group>
        <group group_id="P3">
          <title>Refresh Tears</title>
          <description>Refresh Tears - 1 drop in treated eye, 4 times a day, for 4 days
Refresh Tears: Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Group</title>
          <description>Refresh Tears - 1 drop in treated eye, 4 times a day, for 4 days</description>
        </group>
        <group group_id="B2">
          <title>Acular Group</title>
          <description>Used acular LS</description>
        </group>
        <group group_id="B3">
          <title>Predforte Group</title>
          <description>Used predforte eye drops</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" lower_limit="62" upper_limit="71"/>
                    <measurement group_id="B2" value="69.5" lower_limit="60.5" upper_limit="73"/>
                    <measurement group_id="B3" value="73" lower_limit="66.5" upper_limit="77.5"/>
                    <measurement group_id="B4" value="69" lower_limit="63" upper_limit="72.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Interocular Pressure</title>
        <description>IOP, measured by Goldmann applanation tonometry</description>
        <time_frame>8 weeks</time_frame>
        <population>Reported for subjects for whom all IOP values were available for all of the visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Acular LS</title>
            <description>Acular LS - 1 drop in treated eye, 4 times a day, for 4 days
Acular LS: Details covered in arm description</description>
          </group>
          <group group_id="O2">
            <title>Pred Forte</title>
            <description>Pred Forte - 1 drop in treated eye, 4 times a day, for 4 days
Pred Forte: Details covered in arm description</description>
          </group>
          <group group_id="O3">
            <title>Refresh Tears</title>
            <description>Refresh Tears - 1 drop in treated eye, 4 times a day, for 4 days
Refresh Tears: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Interocular Pressure</title>
          <description>IOP, measured by Goldmann applanation tonometry</description>
          <population>Reported for subjects for whom all IOP values were available for all of the visits.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" spread="3.1"/>
                    <measurement group_id="O2" value="17.0" spread="3.3"/>
                    <measurement group_id="O3" value="17.8" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" spread="2.2"/>
                    <measurement group_id="O2" value="12.4" spread="2.5"/>
                    <measurement group_id="O3" value="13.4" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2" spread="3.3"/>
                    <measurement group_id="O2" value="15.7" spread="2.8"/>
                    <measurement group_id="O3" value="15.6" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" spread="2.6"/>
                    <measurement group_id="O2" value="14.0" spread="2.4"/>
                    <measurement group_id="O3" value="14.6" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" spread="2.3"/>
                    <measurement group_id="O2" value="15.0" spread="1.6"/>
                    <measurement group_id="O3" value="15.8" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Acular LS</title>
          <description>Acular LS - 1 drop in treated eye, 4 times a day, for 4 days
Acular LS: Details covered in arm description</description>
        </group>
        <group group_id="E2">
          <title>Pred Forte</title>
          <description>Pred Forte - 1 drop in treated eye, 4 times a day, for 4 days
Pred Forte: Details covered in arm description</description>
        </group>
        <group group_id="E3">
          <title>Refresh Tears</title>
          <description>Refresh Tears - 1 drop in treated eye, 4 times a day, for 4 days
Refresh Tears: Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Malik Kahook, MD</name_or_title>
      <organization>University of Colorado, Dept. of Ophthalmology</organization>
      <phone>720-848-2501</phone>
      <email>Malik.kahook@ucdenver.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

